Thursday 7 May, 2026
Introduction: Pharmacokinetic (PK) analyses, data evaluation, and simulations assume that absorption of drugs administered orally or otherwise lasts forever since…
Read moreAbstracts
Population Pharmacokinetic Modeling of Vancomycin in Ventricular Assist Device Implanted Patients: Exploration for Role of Hemodynamic Parameters
Thursday 7 May, 2026
Introduction/Objectives: Ventricular assist devices (VADs) are implantable mechanical pumps used in advanced heart failure as bridge-to-transplantation or destination therapy. Despite…
Read moreAN OCULAR EXPOSURE PREDICTION FOR TOPICAL ATROPINE IN HUMANS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING
Thursday 7 May, 2026
Objectives Atropine is widely used in ophthalmology for mydriasis, cycloplegia, and amblyopia treatment. Recently, low-dose atropine has gained increasing attention…
Read moreMODEL-INFORMED FIXED DOSING OF ROZANOLIXIZUMAB IN gMG: PK/PD ADVANTAGES AND COMPARISON FROM OTHER FcRn BLOCKERS
Thursday 7 May, 2026
Objectives–Generalised myasthenia gravis (gMG) is an autoimmune disorder caused by IgG antibodies attacking acetylcholine receptor (AChR) or muscle-specific kinase (MuSK),…
Read moreAn individual patient data meta-analysis of miltefosine pharmacokinetics across clinical forms of leishmaniasis
Thursday 7 May, 2026
Objectives: Miltefosine is the only oral treatment for all clinical forms of leishmaniasis, ranging from self-healing cutaneous leishmaniasis (CL) to…
Read moreArtificial Intelligence/Machine Learning (AI/ML) SubSIG of SxP: A collaboration to advance Pharmacometrics using AI/ML methods
Thursday 7 May, 2026
The Artificial Intelligence and Machine Learning Sub Special Interest Group (AI/ML SubSIG) of the ISoP–ASA Statistics and Pharmacometrics (SxP) SIG…
Read moreModel Based Meta-Analysis of Disease-Free Survival in Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Treated with Mitomycin C or Gemcitabine
Thursday 7 May, 2026
Introduction: Intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) is a heterogeneous disease with variable clinical outcomes, making selection of appropriate…
Read moreMODEL-BASED BRIDGING OF EPLONTERSEN POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS IN CHINESE HEALTHY VOLUNTEERS AND CHINESE PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY SUPPORTS GLOBAL DOSING REGIMEN WITHOUT DOSE ADJUSTMENT
Thursday 7 May, 2026
Objectives Eplontersen is an antisense oligonucleotide-GalNAc conjugate that reduces the amount of circulating transthyretin (TTR) protein by binding to TTR…
Read moreElranatamab Exposure-Safety Analysis in Patients with Relapse or Refractory Multiple Myeloma: Insights from MagnetisMM Studies
Thursday 16 October, 2025
Introduction: Elranatamab (ELRA) is a heterodimeric humanized bispecific antibody approved for treatment of patients with relapsed/refractory multiple myeloma (RRMM). ELRA…
Read moreStep-Wise Population Pharmacokinetic Modeling Approach to Characterize Complex Absorption of Lenacapavir Following SC Administration in Healthy Participants
Thursday 16 October, 2025
Introduction: Lenacapavir (LEN) is a novel long-acting, first-in-class, selective inhibitor of HIV-1 capsid function, currently approved for multidrug resistant HIV-1…
Read more